vs
Side-by-side financial comparison of BioLineRx Ltd. (BLRX) and Token Cat Ltd (TC). Click either name above to swap in a different company.
BioLineRx Ltd. is the larger business by last-quarter revenue ($5.4M vs $2.8M, roughly 2.0× Token Cat Ltd). BioLineRx Ltd. runs the higher net margin — 9.0% vs -3.4%, a 12.3% gap on every dollar of revenue.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
BLRX vs TC — Head-to-Head
Income Statement — Q2 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $2.8M |
| Net Profit | $484.0K | $-93.0K |
| Gross Margin | 83.4% | 79.0% |
| Operating Margin | -107.0% | -206.9% |
| Net Margin | 9.0% | -3.4% |
| Revenue YoY | — | -37.9% |
| Net Profit YoY | 102.6% | 98.3% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $2.8M | ||
| Q2 24 | $5.4M | $4.4M | ||
| Q2 23 | $0 | $12.7M | ||
| Q2 22 | — | $13.3M |
| Q2 25 | — | $-93.0K | ||
| Q2 24 | $484.0K | $-5.6M | ||
| Q2 23 | $-18.5M | $-4.2M | ||
| Q2 22 | — | $-8.4M |
| Q2 25 | — | 79.0% | ||
| Q2 24 | 83.4% | 69.2% | ||
| Q2 23 | — | 63.4% | ||
| Q2 22 | — | 81.0% |
| Q2 25 | — | -206.9% | ||
| Q2 24 | -107.0% | -146.9% | ||
| Q2 23 | — | -59.9% | ||
| Q2 22 | — | -49.6% |
| Q2 25 | — | -3.4% | ||
| Q2 24 | 9.0% | -125.9% | ||
| Q2 23 | — | -33.3% | ||
| Q2 22 | — | -62.9% |
| Q2 25 | — | — | ||
| Q2 24 | $0.00 | — | ||
| Q2 23 | $-0.02 | — | ||
| Q2 22 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.6M | $150.0K |
| Total DebtLower is stronger | — | $1.4M |
| Stockholders' EquityBook value | $13.9M | $4.6M |
| Total Assets | $64.6M | $28.4M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $150.0K | ||
| Q2 24 | $9.6M | $689.0K | ||
| Q2 23 | $10.1M | $3.0M | ||
| Q2 22 | — | $4.8M |
| Q2 25 | — | $1.4M | ||
| Q2 24 | — | $1.8M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | — | $4.6M | ||
| Q2 24 | $13.9M | $-787.0K | ||
| Q2 23 | $21.1M | $9.1M | ||
| Q2 22 | — | $21.4M |
| Q2 25 | — | $28.4M | ||
| Q2 24 | $64.6M | $12.5M | ||
| Q2 23 | $58.9M | $25.1M | ||
| Q2 22 | — | $40.6M |
| Q2 25 | — | 0.30× | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-23.7M |
| Free Cash FlowOCF − Capex | $-25.5M | — |
| FCF MarginFCF / Revenue | -472.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | -52.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-23.7M | ||
| Q2 24 | $-25.4M | $-1.5M | ||
| Q2 23 | $-17.7M | $-7.2M | ||
| Q2 22 | — | $-8.3M |
| Q2 25 | — | — | ||
| Q2 24 | $-25.5M | $-1.5M | ||
| Q2 23 | $-17.8M | — | ||
| Q2 22 | — | $-8.3M |
| Q2 25 | — | — | ||
| Q2 24 | -472.8% | -34.4% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | -62.2% |
| Q2 25 | — | — | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 0.1% |
| Q2 25 | — | — | ||
| Q2 24 | -52.56× | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
